Intratumoral 2141-V11 With Standard Therapy

2141-V11 is a recombinant fully humanized IgG1 monoclonal antibody directed against CD40, which activates the CD40 receptor.

5-FU will be administered as a continuous infusion over 48 hours

The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

Live record on ClinicalTrials.gov →

• Histologically confirmed esophageal, gastric, or gastroesophageal junction adenocarcinoma
• Locally advanced unresectable or metastaticdisease at diagnosis
• On first line systemic therapy including fluoropyrimidine + anti-PD-1 therapy for advanced GEA (e.g. FOLFOX + nivolumab) for a minimum of 3 months and no more than 9 months.
• Platinum chemotherapy included in first line regimen has been discontinued or will be discontinued ≥2 weeks prior to first planned dose of 2141-V11
• Patients in the safety lead-in cohort must be on 5-FU
• Primary esophageal, gastric, or gastroesophageal junction tumor intact and visible at time of enrollment (within 1 month of 2141-V11 treatment initiation) on endoscopy

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.